New drug aims to calm rogue immune attacks on blood cells
NCT ID NCT06534021
First seen May 30, 2026 · Last updated Jun 06, 2026 · Updated 1 time
Summary
This early-stage trial tests a new medicine called IASO-782 in 16 adults with two autoimmune blood diseases: immune thrombocytopenia (low platelets) and warm antibody autoimmune hemolytic anemia (low red blood cells). The main goal is to check the drug's safety and how well people tolerate it. Participants must have failed at least one prior treatment and be on stable doses of other immune-suppressing medicines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.